NCT01172717撤回2 期
Phase II Study of Panitumumab in the Treatment of Carcinoid Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Radiographic measures
研究概览
简要总结
The primary hypothesis of this study is that panitumumab, an inhibitor of the epidermal growth factor receptor (EGFR), is an effective treatment for carcinoid syndrome in people who fail or do not adequately respond to octreotide or other supportive therapies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of metastatic carcinoid tumor and carcinoid syndrome
- •Measurable disease as defined by RECIST criteria or evaluable disease
- •Measurable disease is the presence of at least one measurable lesion. If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology. Measurable lesions are lesions that can be accurately measured in at least one dimension with longest diameter greater than or equal to 20 mm using conventional techniques or greater than or equal to 10 mm with spiral CT scan.
- •Evaluable disease is disease that cannot be measured directly by the size of the tumor but can be evaluated by a validated biomarker assay including 24 hr urine 5-hydroxyindoleacetic acid, serum serotonin, and/or serum chromogranin A.
- •All sites of disease must be evaluated less than or equal to 28 days prior to enrollment.
- •All subjects must be 18 years of age or older.
- •ECOG performance status of 0 to
- •Subjects may have had past or may be receiving current treatment with octreotide.
- •Adequate laboratory parameters with all tests to be performed within 72 hours prior to the first dose.
- •Absolute neutrophil count greater than or equal to 1.5 x 109/L
- •Hemoglobin greater than or equal to 9.0 g/dL
- •Platelet count greater than or equal to 100 x 109/L
- •Serum creatinine less than 1.5 mg/dL
- •Aspartate aminotransferase (AST) less than or equal to 3 times the upper limit of normal, unless with radiographic evidence of liver metastases. If with liver metastases, AST less than 5 times the upper limit of normal.
- •Alanine aminotransferase (ALT) less than or equal to 3 times the upper limit of normal, unless with radiographic evidence of liver metastases. If with liver metastases, AST less than 5 times the upper limit of normal.
- •Total Bilirubin less than or equal to 1.5 times the upper limit of normal.
- •Magnesium level greater than lower limit of normal
- •Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
- •Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Woman and men should use adequate birth control for at least 6 months after the last administration of panitumumab.
- •Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to any study specific procedures.
排除标准
- •Evidence of localized carcinoid tumor amenable to surgical resection or chemoembolization.
- •People who are asymptomatic from their carcinoid tumors.
- •Past treatment with EGFR inhibitors including cetuximab and panitumumab.
- •History of active malignancies requiring treatment in the past 5 years with the exception of resected basal cell carcinoma of the skin.
- •History of interstitial pneumonitis or pulmonary fibrosis.
- •History of cardiac arrhythmia or Q-T prolongation on electrocardiogram.
- •Women who are pregnant or breast feeding.
- •Known infection with human immunodeficiency virus (HIV).
- •Treatment with chemotherapy, biologics, immunotherapy, vaccines or cytokine therapy within 4 weeks prior to study entry. The use of octreotide is not exclusionary.
- •Major surgery, open biopsy or significant traumatic injury within 4 weeks of enrollment.
- •A negative octreotide scan does not exclude study enrollment.
研究组 & 干预措施
Panitumumab
Experimental
Single arm study
干预措施: Panitumumab (Drug)
结局指标
主要结局
Radiographic measures
时间窗: Every 4 cycles
Tumor Marker Evaluations
时间窗: Every 2 cycles
次要结局
- Quality of LIfe(Day 1 each cycle and 1 month follow-up)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck CancerHead and Neck CancerNCT01264328Grupo Español de Tratamiento de Tumores de Cabeza y Cuello40
已完成
2 期
Study to Evaluate Mechanisms of Acquired Resistance to PanitumumabMetastatic Colorectal CancerNCT00891930NantBioScience, Inc.74
撤回
2 期
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the RectumRectal CancerNeoplasm MetastasisNCT00346099NSABP Foundation Inc
已完成
2 期
Phase II study of panitumumab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000011440onprofit Organization Japan Clinical Cancer Research Organization35
终止
2 期
Preoperative Panitumumab and Radiotherapy in Rectal CancerRectal CancerNCT00973193Cliniques universitaires Saint-Luc- Université Catholique de Louvain20